Publications
- Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Current review of immunotherapy and anti-angiogenic lung cancer treatment2019 | Faculty of Medicine in Pilsen
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Do metastases in the brain in a tumor with ALK translocation always mean ineffectiveness of crizotinib therapy?2017 | Faculty of Medicine in Pilsen
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Faculty of Medicine in Pilsen, Faculty of Science
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
Loading network view...